For Q2FY24, Tatva Chintan Pharma Chem’s revenue grew 7.3% YoY but declined 15.5% QoQ to INR 967 Mn. This is mainly driven by robust growth in the SDA segment (44.0% of revenue), a growth of 487.0% YoY to INR 428 Mn due to steady improvement in commercial vehicle sales, and the addition of new customers.